Author:
Brooker Sarah M.,Mencacci Niccolò E.
Funder
Parkinson's Foundation
National Institutes of Health
Subject
Neurology (clinical),Geriatrics and Gerontology,Neurology
Reference25 articles.
1. Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment;Roze;Curr. Opin. Neurol.,2018
2. Twenty years on: myoclonus-dystonia and epsilon-sarcoglycan - neurodevelopment, channel, and signaling dysfunction;Menozzi;Mov. Disord.,2019
3. Defining the epsilon-sarcoglycan (SGCE) gene phenotypic signature in myoclonus-dystonia: a reappraisal of genetic testing criteria;Carecchio;Mov. Disord.,2013
4. Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes;Tezenas du Montcel;J. Med. Genet.,2006
5. A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia;Mencacci;Am. J. Hum. Genet.,2015